Davis Polk is advising Morgan Stanley & Co. LLC, Evercore and Dyal Co. LLC as financial advisers to Bristol-Myers Squibb Company in connection with its approximately $74 billion acquisition of Celgene Corporation. The transaction, which is expected to close in the third quarter of 2019, is subject to shareholder approval and the satisfaction of customary closing conditions and regulatory approvals.
Bristol-Myers Squibb Company engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Celgene Corporation is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases.
The Davis Polk corporate team includes partner Lee Hochbaum and associate Jeffrey Scharfstein. All members of the Davis Polk team are based in the New York office.